Bristol Myers Squibb Company to Issue Quarterly Dividend of $0.63 (NYSE:BMY)

Posted by George Bondi on Sep 17th, 2026

Bristol Myers Squibb Company (NYSE:BMY – Get Free Report) announced a quarterly dividend on Tuesday, September 15th. Stockholders of record on Friday, October 2nd will be given a dividend of 0.63 per share by the biopharmaceutical company on Monday, November 2nd. This represents a c) annualized dividend and a dividend yield of 4.0%. The ex-dividend date is Friday, October 2nd.

Bristol Myers Squibb has raised its dividend by an average of 0.0%per year over the last three years and has raised its dividend annually for the last 17 consecutive years. Bristol Myers Squibb has a payout ratio of 41.5% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Bristol Myers Squibb to earn $6.44 per share next year, which means the company should continue to be able to cover its $2.52 annual dividend with an expected future payout ratio of 39.1%.

Bristol Myers Squibb Stock Performance

Shares of BMY opened at $63.55 on Thursday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The stock has a 50 day moving average price of $63.99 and a two-hundred day moving average price of $60.12. The firm has a market capitalization of $129.80 billion, a P/E ratio of 14.00, a P/E/G ratio of 0.30 and a beta of 0.23. Bristol Myers Squibb has a 52 week low of $42.52 and a 52 week high of $68.64.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.44. The firm had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business’s revenue was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts forecast that Bristol Myers Squibb will post 6.95 earnings per share for the current fiscal year.

Insider Activity at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.05% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its position in Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after buying an additional 8,702,106 shares during the period. State Street Corp boosted its holdings in shares of Bristol Myers Squibb by 1.4% during the fourth quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock worth $5,285,065,000 after purchasing an additional 1,385,206 shares during the period. Geode Capital Management LLC grew its stake in shares of Bristol Myers Squibb by 13.1% in the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after purchasing an additional 6,084,046 shares during the last quarter. Norges Bank purchased a new position in Bristol Myers Squibb during the 4th quarter valued at about $1,947,272,000. Finally, Primecap Management Co. CA bought a new position in Bristol Myers Squibb during the 2nd quarter valued at approximately $1,436,115,000. Institutional investors own 76.41% of the company’s stock.

About Bristol Myers Squibb

(Get Free Report)

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.